SEARCH:   Advanced

Blood, 15 October 2008, Vol. 112, No. 8, pp. 3126-3129. Prepublished online as a Blood First Edition Paper on July 15, 2008; DOI 10.1182/blood-2008-05-154013. This Article Full Text Full Text (PDF) Supplemental Table All Versions of this Article: blood-2008-05-154013v1 112/8/3126    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by O'Shea, D. Articles by Fitzgibbon, J. Search for Related Content PubMed PubMed Citation Articles by O'Shea, D. Articles by Fitzgibbon, J. Related Collections Neoplasia Brief Reports Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief Report The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival Derville O'Shea1, Ciarán O'Riain1, Claire Taylor2, Rachel Waters3, Emanuela Carlotti1, Finlay MacDougall1, John Gribben1, Andreas Rosenwald4, German Ott4,5, Lisa M. Rimsza6, Erlend B. Smeland7,8, Nathalie Johnson9, Elias Campo10, Timothy C. Greiner11, Wing C. Chan11, Randy D. Gascoyne9, George Wright12, Louis M. Staudt13, T. Andrew Lister1, and Jude Fitzgibbon1 1 Centre for Medical Oncology, Barts and the London School of Medicine, London, United Kingdom; 2 Mutation Detection Facility, St James's University Hospital, Leeds, United Kingdom; 3 Centre for Statistics in Medicine, Oxford University, Oxford, United Kingdom; 4 Institute of Pathology, University of Würzburg, Würzburg, Germany; 5 Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany; 6 Department of Pathology and Arizona Cancer Center, University of Arizona, Tucson; 7 Department of Immunology, Institute for Cancer Research, Rikshospitalet University Hospital, Oslo, Norway; 8 Centre for Cancer Biomedicine, Faculty Division, Norwegian Radium Hospital, University of Oslo, Oslo, Norway; 9 Department of Pathology and Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC; 10 Hematopathology Section, Department of Pathology, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain; 11 Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha; and 12 Biometric Research Branch and 13 Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD The International Prognostic Index and the Follicular Lymphoma International Prognostic Index are widely used for the risk assessment of follicular lymphoma (FL). Although molecular studies have provided insight into the biology of FL, no molecular marker has impacted on treatment stratification. Because TP53 mutations are associated with poor prognosis in hematologic malignancies, we investigated the prognostic value of TP53 mutation at diagnosis in FL. Heterozygous TP53 mutation was detected in 12 of 185 (6%) analyzed cases. Mutation was associated with older age (P = .02) and higher International Prognostic Index score (P = .04). On multivariate analysis, TP53 mutation correlated with shorter progression-free survival (P < .001) and overall survival (P = .009). TP53 mutation was associated with low expression of the immune-response 1 gene expression signature (P = .016) and with an unfavorable gene expression-based survival predictor score (P < .001), demonstrating for the first time that molecular features of the malignant cell may correlate with the nature of the immune response in FL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: P53 mutations in lymphomas: position matters Arnold J. Levine and Evan Vosburgh Blood 2008 112: 2997-2998. [Full Text] [PDF] This article has been cited by other articles: D. Dornan, F. Bennett, Y. Chen, M. Dennis, D. Eaton, K. Elkins, D. French, M. A. T. Go, A. Jack, J. R. Junutula, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma Blood, September 24, 2009; 114(13): 2721 - 2729. [Abstract] [Full Text] [PDF] G. Ott and A. Rosenwald Molecular pathogenesis of follicular lymphoma Haematologica, December 1, 2008; 93(12): 1773 - 1776. [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020